Back

CStone’s CS2009 posts 100% response rate in first-line NSCLC subgroup

Verifying
  • CStone Pharmaceuticals reported updated CS2009 clinical data across multiple cancer cohorts.
  • CS2009 achieved 100% ORR and 100% DCR at 30 mg/kg in selected first-line NSCLC patients.
  • CStone plans global Phase III trials by year-end 2026 and two ESMO 2026 presentations.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.